| Literature DB >> 31910384 |
Pamela Sue Becker1, Elizabeth A Griffiths2, Laura M Alwan3, Kimo Bachiashvili4, Anna Brown5, Rita Cool6, Peter Curtin7, Shira Dinner8, Ivana Gojo9, Ashley Hicks10, Avyakta Kallam11, Wajih Zaheer Kidwai12, Dwight D Kloth13, Eric H Kraut14, Daniel Landsburg15, Gary H Lyman3, Ryan Miller16, Sudipto Mukherjee17, Shiven Patel18, Lia E Perez19, Adam Poust20, Raajit Rampal21, Rachel Rosovsky22, Vivek Roy23, Hope S Rugo24, Sepideh Shayani25, Sumithira Vasu14, Martha Wadleigh26, Kelly Westbrook27, Peter Westervelt28, Jennifer Burns29, Jennifer Keller29, Lenora A Pluchino29.
Abstract
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.Entities:
Mesh：
Substances：
Year: 2020 PMID： 31910384 DOI： 10.6004/jnccn.2020.0002
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908